Hereditary Breast and Ovarian Cancer Clinical Trial
Official title:
University of Southern California (USC) Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing
This study is about understanding the use of a genetic test (Myriad Genetics myRisk panel) that analyzes 25 genes related to different hereditary cancer conditions. The investigators hope to learn more about how this type of genetic test is used clinically. The investigators also hope to understand more about the experience of individuals and families who undergoing this test of genetic testing.
If a patient is identified as fulfilling one of the screening criteria, possible
participants should be referred to the Cancer Genetics Clinic for further evaluation for
possible enrollment into the study. A pre-clinic questionnaire will be sent to the patients
prior to their assessment in cancer genetics clinic in order to obtain baseline information
that will be used to inform changes during follow-up. Assessments performed exclusively to
determine eligibility for this study will be done only after obtaining informed consent.
Assessments performed for clinical indications (not exclusively to determine study
eligibility) may be used for baseline values even if the studies were done before informed
consent was obtained.
All screening procedures must be performed on the day of registration unless otherwise
stated. The screening procedures include:
1. Medical history -Complete medical and surgical history, family history including a
multi-generation family pedigree, and social history
2. Demographics - Age, gender, race, ethnicity
3. Review subject eligibility criteria
4. Physical exam including vital signs, height and weight
5. Blood draw for correlative studies
6. DNA from whole blood will be isolated
Intervention Procedure:
Approximately 15 ml of blood will be drawn at the time of enrollment (one time blood draw)
and sent to Myriad Genetics and Laboratories for analysis of 25 genes using next generation
sequencing. This platform will sequence 25 genes in one experimental run and the results
will be sent back to the cancer genetics clinic for interpretation and disclosure.
Randomization of the patient Population:
After results are given to the patient they will be randomized into 4 groups:
- Patients identified with a mutation in a gene not commonly tested for prior to the
advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2,
EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not
meet clinical criteria for the underlying syndrome (Stanford accrual goal is 62/USC 62)
- Patients identified with a variant of unknown significance (VUS) of any gene of any
nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and
EPCAM).
Stanford target accrual is 50 and 50 for USC.
- Patients who test negative for all the genes tested. Target goal is 50 for Stanford/50
for USC for the study.
- All other participants who do not meet any of the above criteria or fall into one of
these groups after the target goal is met for that group. Only participants who are in
the 1st three groups will be asked to complete questionnaires for the duration of the
study (up to 60 months after enrollment)
Follow-up Procedures:
Patients (as noted above) will be followed at 3 months, 6 months, 12 months, 24 months, 36
months, 48 months, and 60 months
• At 3 months and 6 months after disclosure of genetic testing results, follow up
questionnaires will ask if participants had initiated or intend to undergo any of the
following risk reducing interventions and/or treatment: (i) Cancer surveillance/screening:
breast MRI, mammograms, self-breast examinations, thyroid ultrasound, dermatology exams,
urinalysis, upper endoscopy, colonoscopy, endometrial biopsy, transvaginal ultrasound, or
other imaging (i.e. whole body rapid MRI) (ii) Chemoprevention/Behavior Modification:
Tamoxifen, Oral Contraceptives (OCP), Raloxifene, Sulindac, Abstinence from Smoking (iii)
Prophylactic procedures: Mastectomy, TAHBSO, polypectomy, total and segmental colectomy (iv)
Cancer Treatment: aggregated pharmacologic and radiation therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03246841 -
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
|
N/A | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Terminated |
NCT04668521 -
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
|
||
Completed |
NCT03075540 -
Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer
|
N/A | |
Enrolling by invitation |
NCT05721326 -
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
|
N/A | |
Recruiting |
NCT04407611 -
Scalable Communication Modalities for Returning Genetic Research Results
|
N/A | |
Recruiting |
NCT02302742 -
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
|
||
Recruiting |
NCT02516540 -
Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers
|
N/A | |
Recruiting |
NCT05409222 -
Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)
|
||
Enrolling by invitation |
NCT05130606 -
CONTIGO - Informing Latinas About HBOC Risk
|
N/A | |
Completed |
NCT03511690 -
Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment
|
N/A | |
Completed |
NCT02087592 -
Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers
|
N/A | |
Active, not recruiting |
NCT01608074 -
Radical Fimbriectomy for Young BRCA Mutation Carriers
|
N/A | |
Not yet recruiting |
NCT03979612 -
Evaluation of the Adhesion to the GENEPY Network
|
||
Terminated |
NCT04508764 -
Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome
|
N/A | |
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|
||
Completed |
NCT02786147 -
Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
|
||
Recruiting |
NCT03124212 -
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
|